Aquestive Therapeutics develops and commercializes medicines delivered as orally dissolving thin films rather than traditional tablets or injections. Its proprietary PharmFilm technology places the dose on a small strip that dissolves in the mouth, aiming for convenient dosing and distinctive absorption profiles. The company focuses on central nervous system and other specialty conditions, and also partners with other firms to formulate their drugs on its film platform.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 8.7 | — | -22.9 | — |
| Q2 2025 | 10 | — | -13.6 | — |
| Q3 2025 | 12.8 | — | -15.4 | — |
| Q4 2025 | 13 | — | -31.9 | — |
| Q1 2026 | 14.4 | 65.7% | -8.1 | — |
| Q2 2026 | 13.8 | 38.1% | -22.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Crane Harbor Acquisition Corp. II (CRAN), AngioDynamics, Inc. (ANGO), AMERISAFE, Inc. (AMSF), Private Bancorp of America, Inc. (PBAM), Gores Holdings X, Inc. (GTEN), Evolus, Inc. (EOLS)